Key result
Treatment with chemotherapy and proton beam therapy resulted in the patient remaining disease-free with a preserved left ventricular ejection fraction of 55% to 60% at 5-year follow-up.
Why the study?
Unresectable mediastinal soft tissue sarcomas are often aggressive and associated with a poor prognosis.
Case Report (n=1)
Proton beam therapy combined with chemotherapy may provide long-term disease-free survival with preserved cardiac function in pediatric patients with unresectable mediastinal and pericardial spindle cell sarcoma.
Answers are grounded in this paper and cite their sources.
Caution against routine adoption from single case; leaves open proton therapy potential for cardiac preservation in rare pediatric sarcomas.
Unresectable mediastinal soft tissue sarcomas are often aggressive and associated with a poor prognosis. A 17-year-old male presented with progressive fatigue, shortness of breath, and heart palpitations secondary to an extensive mass involving the mediastinum and pericardium. He was treated with chemotherapy per protocol Children's Oncology Group Protocol ARST0332 and proton beam therapy to the involved mediastinum, pericardium, and heart. At the 5-year follow-up evaluation, he remained disease-free on surveillance imaging. An echocardiogram revealed a 55% to 60% left ventricular ejection fraction. Given the patient's extended survival, we present the oncologic rationale for treatment and considerations of late toxicity.
No takes yet. Share an insight, caveat, or question.
Laughlin et al. (2023) conducted a case report in Unresectable mediastinal and pericardial spindle cell sarcoma (n=1). Chemotherapy and proton beam therapy was evaluated on Disease-free survival and left ventricular ejection fraction. Treatment with chemotherapy and proton beam therapy resulted in the patient remaining disease-free with a preserved left ventricular ejection fraction of 55% to 60% at 5-year follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: